Daniel E. Fürst
Impact in
- Rheumatology top 0.01%
- Rheumatoid Arthritis Research and Therapies
- Spondyloarthritis Studies and Treatments
- Systemic Lupus Erythematosus Research
- Pathology and Forensic Medicine top 0.1%
- Systemic Sclerosis and Related Diseases
Papers in
- Rheumatology 158
- Rheumatoid Arthritis Research and Therapies 145
- Spondyloarthritis Studies and Treatments 6
-
- Systemic Sclerosis and Related Diseases 81
- Co-authors
- Michael H. Weisman (16 shared papers)Paul E. Emery (14 shared papers)Peter E. Lipsky (6 shared papers)Ravinder Nath Maini (6 shared papers)E. William St. Clair (4 shared papers)Joachim R. Kalden (3 shared papers)Marc Feldmann (3 shared papers)Ferdinand C. Breedveld (3 shared papers)
- Journals
- Annals of the Rheumatic Diseases (35 papers)The Journal of Rheumatology (19 papers)Lara D. Veeken (18 papers)Seminars in Arthritis and Rheumatism (11 papers)Arthritis Care & Research (11 papers)
- Partner nations
- United StatesUnited KingdomItaly
In The Last Decade
Daniel E. Fürst
286 papers receiving 26.5k citations
Daniel E. Fürst's Hit Papers
Peers
Comparison fields: 5 of 166
- Rheumatology 14.4k
- Pathology and Forensic Medicine 4.4k
- Immunology 1.8k
- Orthopedics and Sports Medicine 506
- Nephrology 497
Countries citing papers authored by Daniel E. Fürst
This map shows the geographic impact of Daniel E. Fürst's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel E. Fürst with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel E. Fürst more than expected).
Fields of papers citing papers by Daniel E. Fürst
This network shows the impact of papers produced by Daniel E. Fürst. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel E. Fürst. The network helps show where Daniel E. Fürst may publish in the future.
Co-authors
The 25 scholars most cited alongside Daniel E. Fürst, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 289 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Infliximab and Methotrexate in the Treatment of Rheumatoid Arthritis Hit paper breakdown → | 2000 | 2600 |
| 2 | American college of rheumatology preliminary definition of improvement in rheumatoid arthritis Hit paper breakdown → | 1995 | 2323 |
| 3 | Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial Hit paper breakdown → | 1999 | 2021 |
| 4 | The American college of rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials Hit paper breakdown → | 1993 | 1412 |
| 5 | 2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease‐modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis Hit paper breakdown → | 2012 | 1390 |
| 6 | American College of Rheumatology/European League Against Rheumatism Provisional Definition of Remission in Rheumatoid Arthritis for Clinical Trials Hit paper breakdown → | 2011 | 663 |
| 7 | American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid‐induced osteoporosis Hit paper breakdown → | 2010 | 585 |
| 8 | Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: Results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT) Hit paper breakdown → | 2005 | 541 |
| 9 | 1998 | 516 | |
| 10 | Methotrexate for Rheumatoid Arthritis Hit paper breakdown → | 1994 | 498 |
| 11 | 1994 | 453 | |
| 12 | 2004 | 437 | |
| 13 | 1999 | 393 | |
| 14 | 2005 | 389 | |
| 15 | 2006 | 363 | |
| 16 | 2011 | 347 | |
| 17 | 2012 | 319 | |
| 18 | 2007 | 284 | |
| 19 | 1999 | 260 | |
| 20 | 2012 | 250 |
About Daniel E. Fürst
Daniel E. Fürst is a scholar working on Rheumatology, Pathology and Forensic Medicine, Pharmacology, Pharmacology and Pulmonary and Respiratory Medicine, having authored 289 papers that have together received 28.4k indexed citations. Recurring topics across this work include Rheumatoid Arthritis Research and Therapies (145 papers), Systemic Sclerosis and Related Diseases (81 papers), Inflammatory mediators and NSAID effects (10 papers), Pulmonary Hypertension Research and Treatments (7 papers), Pharmacogenetics and Drug Metabolism (6 papers), Statistical Methods in Clinical Trials (6 papers), Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (6 papers) and Spondyloarthritis Studies and Treatments (6 papers). The work is most often cited by research in Rheumatology (14.4k citations), Pathology and Forensic Medicine (4.4k citations), Immunology (1.8k citations), Orthopedics and Sports Medicine (506 citations) and Nephrology (497 citations). Daniel E. Fürst has collaborated with scholars based in United States, United Kingdom and Italy. Frequent co-authors include Michael H. Weisman, Paul E. Emery, Peter E. Lipsky, Ravinder Nath Maini, E. William St. Clair, Joachim R. Kalden, Marc Feldmann, Ferdinand C. Breedveld, Gregory R. Harriman and Josef S Smolen. Their work appears in journals such as Annals of the Rheumatic Diseases, The Journal of Rheumatology, Lara D. Veeken, Seminars in Arthritis and Rheumatism and Arthritis Care & Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.